17 results on '"Stelitano, Caterina"'
Search Results
2. High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 – VERITAS study
- Author
-
Mauro, Francesca R., primary, Starza, Irene Della, additional, Messina, Monica, additional, Reda, Gianluigi, additional, Trentin, Livio, additional, Coscia, Marta, additional, Sportoletti, Paolo, additional, Orsucci, Lorella, additional, Arena, Valentina, additional, Casaluci, Gloria Margiotta, additional, Marasca, Roberto, additional, Murru, Roberta, additional, Laurenti, Luca, additional, Ilariucci, Fiorella, additional, Stelitano, Caterina, additional, Mannina, Donato, additional, Massaia, Massimo, additional, Rigolin, Gian Matteo, additional, Scarfò, Lydia, additional, Marchetti, Monia, additional, Levato, Luciano, additional, Tani, Monica, additional, Arcari, Annalisa, additional, Musuraca, Gerardo, additional, Deodato, Marina, additional, Galieni, Piero, additional, Patrizi, Valeria Belsito, additional, Gottardi, Daniela, additional, Liberati, Anna Marina, additional, Giordano, Annamaria, additional, Molinari, Maria Chiara, additional, Pietrasanta, Daniela, additional, Mattiello, Veronica, additional, Visentin, Andrea, additional, Vitale, Candida, additional, Albano, Francesco, additional, Neri, Antonino, additional, De Novi, Lucia Anna, additional, De Propris, Maria Stefania, additional, Nanni, Mauro, additional, Del Giudice, Ilaria, additional, Guarini, Anna, additional, Fazi, Paola, additional, Vignetti, Marco, additional, Piciocchi, Alfonso, additional, Cuneo, Antonio, additional, and Foà, Robin, additional
- Published
- 2023
- Full Text
- View/download PDF
3. Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trial
- Author
-
Bruna, Riccardo, primary, Benedetti, Fabio, additional, Boccomini, Carola, additional, Patti, Caterina, additional, Barbui, Anna Maria, additional, Pulsoni, Alessandro, additional, Musso, Maurizio, additional, Liberati, Anna Marina, additional, Gini, Guido, additional, Castellino, Claudia, additional, Rossini, Fausto, additional, Ciceri, Fabio, additional, Rota-Scalabrini, Delia, additional, Stelitano, Caterina, additional, Di Raimondo, Francesco, additional, Tucci, Alessandra, additional, Devizzi, Liliana, additional, Zoli, Valerio, additional, Zallio, Francesco, additional, Narni, Franco, additional, Dondi, Alessandra, additional, Parvis, Guido, additional, Semenzato, Gianpietro, additional, Lanza, Francesco, additional, Perrone, Tommasina, additional, Angrilli, Francesco, additional, Billio, Atto, additional, Gueli, Angela, additional, Mantoan, Barbara, additional, Rambaldi, Alessandro, additional, Gianni, Alessandro Massimo, additional, Corradini, Paolo, additional, Passera, Roberto, additional, Ladetto, Marco, additional, and Tarella, Corrado, additional
- Published
- 2019
- Full Text
- View/download PDF
4. MYC protein expression scoring and its impact on the prognosis of aggressive B-cell lymphoma patients
- Author
-
Ambrosio, Maria R., primary, Lazzi, Stefano, additional, Bello, Giuseppe Lo, additional, Santi, Raffaella, additional, Porro, Leonardo Del, additional, de Santi, Maria M., additional, Guazzo, Raffaella, additional, Mundo, Lucia, additional, Rigacci, Luigi, additional, Kovalchuck, Sofia, additional, Onyango, Noel, additional, Fabbri, Alberto, additional, Cencini, Emanuele, additional, Zinzani, Pier Luigi, additional, Zaja, Francesco, additional, Angrilli, Francesco, additional, Stelitano, Caterina, additional, Cabras, Maria G., additional, Spataro, Giuseppe, additional, Bob, Roshanak, additional, Menter, Thomas, additional, Granai, Massimo, additional, Cevenini, Gabriele, additional, Naresh, Kikkeri N., additional, Stein, Harald, additional, Sabattini, Elena, additional, and Leoncini, Lorenzo, additional
- Published
- 2018
- Full Text
- View/download PDF
5. Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana Linfomi
- Author
-
Zaja, Francesco, primary, Ferrero, Simone, additional, Stelitano, Caterina, additional, Ferrari, Angela, additional, Salvi, Flavia, additional, Arcari, Annalisa, additional, Musuraca, Gerardo, additional, Botto, Barbara, additional, Spina, Michele, additional, Cellini, Claudia, additional, Patti, Caterina, additional, Liberati, Anna M., additional, Minotto, Claudia, additional, Pileri, Stefano A., additional, Ceccarelli, Manuela, additional, Volpetti, Stefano, additional, Ferranti, Antonella, additional, Drandi, Daniela, additional, Montechiarello, Elisa, additional, Ladetto, Marco, additional, Carmichael, James, additional, and Fanin, Renato, additional
- Published
- 2017
- Full Text
- View/download PDF
6. MYC protein expression scoring and its impact on the prognosis of aggressive B-cell lymphoma patients
- Author
-
Massimo Granai, Maria Raffaella Ambrosio, Alberto Fabbri, Elena Sabattini, Raffaella Santi, Roshanak Bob, Kikkeri N. Naresh, Emanuele Cencini, Stefano Lazzi, Harald Stein, Maria Giuseppina Cabras, Raffaella Guazzo, Sofia Kovalchuck, Giuseppe Lo Bello, Luigi Rigacci, Francesco Zaja, Gabriele Cevenini, Noel Onyango, Maria Margherita De Santi, Caterina Stelitano, Giuseppe Spataro, Leonardo Del Porro, Lucia Mundo, Lorenzo Leoncini, Pier Luigi Zinzani, Thomas Menter, Francesco Angrilli, Ambrosio, Maria R., Lazzi, Stefano, Bello, Giuseppe Lo, Santi, Raffaella, Porro, Leonardo Del, de Santi, Maria M., Guazzo, Raffaella, Mundo, Lucia, Rigacci, Luigi, Kovalchuck, Sofia, Onyango, Noel, Fabbri, Alberto, Cencini, Emanuele, Zinzani, Pier Luigi, Zaja, Francesco, Angrilli, Francesco, Stelitano, Caterina, Cabras, Maria G., Spataro, Giuseppe, Bob, Roshanak, Menter, Thoma, Granai, Massimo, Cevenini, Gabriele, Naresh, Kikkeri N., Stein, Harald, Sabattini, Elena, Leoncini, Lorenzo, Ambrosio, Maria R, de Santi, Maria M, Cabras, Maria G, and Naresh, Kikkeri N
- Subjects
Adult ,Male ,medicine.medical_specialty ,Lymphoma, B-Cell ,MYC, aggressive B-cell lymphoma ,Aggressive Non-Hodgkin's Lymphoma ,Disease-Free Survival ,Immunophenotyping ,Proto-Oncogene Proteins c-myc ,Text mining ,Quality of life ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,Medicine ,MYC protein expression, prognosis, aggressive B-cell lymphoma ,Online Only Articles ,B-cell lymphoma ,Cyclophosphamide ,Survival rate ,Aged ,Regulation of gene expression ,Hematology ,business.industry ,Middle Aged ,medicine.disease ,Lymphoma ,Quality of Life ,Gene Expression Regulation, Neoplastic ,Survival Rate ,Doxorubicin ,Vincristine ,Cancer research ,Prednisone ,Female ,Rituximab ,business - Abstract
This study examined the reproducibility of MYC and BCL-2 immunohistochemical scoring as well as the impact of higher expression of both proteins (double expressor status, DE) on survival and progression in a large retrospective cohort of aggressive B-cell lymphoma patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) or R-CHOP-like regimens with a median follow up of 67 months (range 0–138). We also investigated possible MYC protein expression cut offs with the highest reproducibility among pathologists and predictability of gene translocation. We showed that immunohistochemistry (IHC) for MYC and BCL-2 is highly reproducible when cut-off values of >70% for MYC and >50% for BCL-2 are used. This threshold not only predicts the presence of rearrangements (with respect to MYC), but is also clinically valuable. In fact, it identifies a subset of patients who are poor responders and who may benefit from alternate therapeutic strategies
- Published
- 2018
7. MYC protein expression scoring and its impact on the prognosis of aggressive B-cell lymphoma patients.
- Author
-
Ambrosio MR, Lazzi S, Bello GL, Santi R, Porro LD, de Santi MM, Guazzo R, Mundo L, Rigacci L, Kovalchuck S, Onyango N, Fabbri A, Cencini E, Zinzani PL, Zaja F, Angrilli F, Stelitano C, Cabras MG, Spataro G, Bob R, Menter T, Granai M, Cevenini G, Naresh KN, Stein H, Sabattini E, and Leoncini L
- Subjects
- Adult, Aged, Cyclophosphamide administration & dosage, Disease-Free Survival, Doxorubicin administration & dosage, Female, Humans, Male, Middle Aged, Prednisone administration & dosage, Rituximab administration & dosage, Survival Rate, Vincristine administration & dosage, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Gene Expression Regulation, Neoplastic drug effects, Lymphoma, B-Cell drug therapy, Lymphoma, B-Cell mortality, Lymphoma, B-Cell pathology, Proto-Oncogene Proteins c-myc biosynthesis
- Published
- 2019
- Full Text
- View/download PDF
8. The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study.
- Author
-
Rossi D, Bruscaggin A, La Cava P, Galimberti S, Ciabatti E, Luminari S, Rigacci L, Tucci A, Pulsoni A, Bertoldero G, Vallisa D, Rusconi C, Spina M, Arcaini L, Angrilli F, Stelitano C, Merli F, Gaidano G, Federico M, and Palumbo GA
- Subjects
- Aged, Antibiotics, Antineoplastic administration & dosage, Antibiotics, Antineoplastic therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Doxorubicin administration & dosage, Doxorubicin therapeutic use, Female, Humans, Kaplan-Meier Estimate, Lymphoma, Follicular diagnosis, Lymphoma, Follicular drug therapy, Lymphoma, Follicular mortality, Male, Middle Aged, MutL Protein Homolog 1, Neoplasm Grading, Neoplasm Metastasis, Neoplasm Staging, Polymorphism, Single Nucleotide, Prognosis, Receptors, IgG genetics, Treatment Failure, Treatment Outcome, Adaptor Proteins, Signal Transducing genetics, Genotype, Lymphoma, Follicular genetics, Nuclear Proteins genetics
- Abstract
Though most follicular lymphoma biomarkers rely on tumor features, the host genetic background may also be relevant for outcome. Here we aimed at verifying the contribution of candidate polymorphisms of FCγ receptor, DNA repair and detoxification genes to prognostic stratification of follicular lymphoma treated with immunochemotherapy. The study was based on 428 patients enrolled in the FOLL05 prospective trial that compared three standard-of-care regimens (rituximab-cyclophosphamide-vincristine-prednisone versus rituximab-cyclophosphamide-doxorubicin-vincristine-prednisone versus rituximab-fludarabine-mitoxantrone) for the first line therapy of advanced follicular lymphoma. Polymorphisms were genotyped on peripheral blood DNA samples. The primary endpoint was time to treatment failure. Polymorphisms of FCGR2A and FCGR3A, which have been suggested to influence the activity of rituximab as a single agent, did not affect time to treatment failure in the pooled analysis of the three FOLL05 treatment arms that combined rituximab with chemotherapy (P=0.742, P=0.252, respectively). These results were consistent even when the analysis was conducted by intention to treat, indicating that different chemotherapy regimens and loads did not interact differentially with the FCGR2A and FCGR3A genotypes. The genotype of MLH1, which regulates the genotoxic effect of doxorubicin, significantly affected time to treatment failure in patients in the rituximab-cyclophosphamide-doxorubicin-vincristine-prednisone arm (P=0.001; q<0.1), but not in arms in which patients did not receive doxorubicin (i.e., the rituximab-cyclophosphamide-vincristine-prednisone and rituximab-fludarabine-mitoxantrone arms). The impact of MLH1 on time to treatment failure was independent after adjusting for the Follicular Lymphoma International Prognostic Index and other potential confounding variables by multivariate analysis. These data indicate that MLH1 genotype is a predictor of failure to benefit from rituximab-cyclophosphamide-doxorubicin-vincristine-prednisone treatment in advanced follicular lymphoma and confirm that FCGR2A and FCGR3A polymorphisms have no impact when follicular lymphoma is treated with rituximab plus chemotherapy (clinicaltrials.gov identifier: NCT00774826)., (Copyright© Ferrata Storti Foundation.)
- Published
- 2015
- Full Text
- View/download PDF
9. Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana Linfomi.
- Author
-
Merli M, Visco C, Spina M, Luminari S, Ferretti VV, Gotti M, Rattotti S, Fiaccadori V, Rusconi C, Targhetta C, Stelitano C, Levis A, Ambrosetti A, Rossi D, Rigacci L, D'Arco AM, Musto P, Chiappella A, Baldini L, Bonfichi M, and Arcaini L
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols adverse effects, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Combined Modality Therapy, Female, Hepatitis C virology, Humans, Lymphoma, Large B-Cell, Diffuse diagnosis, Lymphoma, Large B-Cell, Diffuse drug therapy, Male, Middle Aged, Neoplasm Metastasis, Neoplasm Staging, Patient Outcome Assessment, Prognosis, Retrospective Studies, Treatment Outcome, Young Adult, Hepatitis C complications, Lymphoma, Large B-Cell, Diffuse complications, Lymphoma, Large B-Cell, Diffuse mortality
- Abstract
A specific prognostication score for hepatitis C virus-positive diffuse large B-cell lymphomas is not available. For this purpose, the Fondazione Italiana Linfomi (FIL, Italian Lymphoma Foundation) carried out a multicenter retrospective study on a large consecutive series of patients with hepatitis C virus-associated diffuse large B-cell lymphoma to evaluate the prognostic impact of clinical and virological features and to develop a specific prognostic score for this subset of patients. All prognostic evaluations were performed on 535 patients treated with an anthracycline-based induction regimen (with rituximab in 255 cases). Severe hepatotoxicity was observed in 14% of patients. The use of rituximab was not associated with increased rate of severe hepatotoxicity. Three-year overall survival and progression-free survival were 71% and 55%, respectively. At multivariate analysis, ECOG performance status of 2 or over, serum albumin below 3.5 g/dL and HCV-RNA viral load over 1000 KIU/mL retained prognostic significance. We combined these 3 factors in a new "HCV Prognostic Score" able to discriminate 3 risk categories with different overall and progression-free survival (low=0; intermediate=1; high-risk ≥2 factors; P<0.001). This score retained prognostic value in the subgroups of patients treated with and without rituximab (P<0.001). The new score performed better than the International Prognostic Index at multivariate analysis and Harrel C-statistic. With the use of three readily available factors (performance status, albumin level and HCV-RNA viral load), the new "HCV Prognostic Score" is able to identify 3 risk categories with different survival, and may be a useful tool to predict the outcome of hepatitis C virus-associated diffuse large B-cell lymphomas.
- Published
- 2014
- Full Text
- View/download PDF
10. Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study.
- Author
-
Sacchi S, Marcheselli L, Bari A, Marcheselli R, Pozzi S, Luminari S, Lombardo M, Buda G, Lazzaro A, Gobbi PG, Stelitano C, Morabito F, Quarta G, and Brugiatelli M
- Subjects
- Acute Disease, Adult, Age Factors, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols adverse effects, Breast Neoplasms epidemiology, Breast Neoplasms etiology, Female, Follow-Up Studies, Hematopoietic Stem Cell Transplantation adverse effects, Humans, Incidence, Italy epidemiology, Leukemia, Myeloid epidemiology, Leukemia, Myeloid etiology, Male, Middle Aged, Myelodysplastic Syndromes epidemiology, Myelodysplastic Syndromes etiology, Neoplasms, Radiation-Induced epidemiology, Neoplasms, Radiation-Induced etiology, Neoplasms, Second Primary etiology, Radioimmunotherapy adverse effects, Radiotherapy adverse effects, Transplantation, Autologous adverse effects, Vidarabine administration & dosage, Vidarabine adverse effects, Vidarabine analogs & derivatives, Lymphoma, Non-Hodgkin therapy, Neoplasms, Second Primary epidemiology
- Abstract
Background: Relatively little information is available on the incidence of secondary cancer in non-Hodgkin's lymphoma. The aim of this long-term follow-up study was to determine the incidence, the time free of second tumors, and risk factors for developing secondary cancer in a homogeneous group of patients with non-Hodgkin's lymphoma., Design and Methods: We evaluated a total of 563 patients with indolent non-Hodgkin's lymphoma enrolled in Gruppo Italiano Studio Linfomi trials from 1988 to 2003., Results: After a median follow-up of 62 months, 39 patients (6.9%) developed secondary cancer: 12 myelodysplastic syndromes/acute myeloid leukemia, and 27 solid tumors. The overall standardized incidence ratio of secondary malignancy in patients with non-Hodgkin's lymphoma was higher than the risk of malignancy in the general population. The standardized incidence ratio was elevated in male patients and in patients under 65 years old at first treatment. Overall, the cumulative incidence of secondary cancer at 12 years was 10.5%, after correction in a competing-risk model. Univariate and multivariate Cox regression analyses showed that older age at the time of diagnosis, male sex, and fludarabine-containing therapy had significant negative impacts on the time free of second tumors., Conclusions: We have identified subgroups of non-Hodgkin's lymphoma patients with increased standardized incidence ratios of secondary malignancy and variables that have a negative impact on the time free of second tumors. This information could help physicians to select the most appropriate treatments. Finally, taking into account the possible occurrence of secondary neoplasia, long-term monitoring must be considered.
- Published
- 2008
- Full Text
- View/download PDF
11. Prognostic relevance of serum beta2 microglobulin in patients with follicular lymphoma treated with anthracycline-containing regimens. A GISL study.
- Author
-
Federico M, Guglielmi C, Luminari S, Mammi C, Marcheselli L, Gianelli U, Maiorana A, Merli F, Bellei M, Pozzi S, Stelitano C, Lazzaro A, Gobbi PG, Baldini L, Bergantini S, Fregoni V, and Brugiatelli M
- Subjects
- Adult, Aged, Antibiotics, Antineoplastic therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Female, Humans, Lymphoma, Follicular mortality, Male, Middle Aged, Multivariate Analysis, Prognosis, Regression Analysis, Survival Rate, Anthracyclines therapeutic use, Lymphoma, Follicular diagnosis, Lymphoma, Follicular drug therapy, Predictive Value of Tests, beta 2-Microglobulin blood
- Abstract
Background and Objectives: Although serum beta2 microglobulin (beta2 M) is an easy parameter to measure, and over-expressed in a large number of lymphoproliferative diseases, its prognostic value has been largely underestimated. The present study examined the influence of beta2M levels on overall survival (OS) of patients with follicular lymphoma (FL)., Design and Methods: The prognostic role of beta2M was evaluated in 236 patients with FL identified from the databases of the Gruppo Italiano per lo Studio dei Linfomi (GISL) and treated with anthracycline-based regimens from 1993 to 2003., Results: Elevated serum beta2M levels were found in 82 patients (35%). According to multivariate logistic regression analysis, elevated beta2M levels were associated with elevated lactate dehydrogenase (LDH) (p=0.021), age (p=0.029), and number of involved nodal areas (p<0.001). The percentage of elevated beta2M levels increased progressively with increasing FLIPI scores (17%, 38%, and 63% in the low-, intermediate-, and high-risk groups, respectively). Five-year OS was 61% (95% CI, 47-73%) and 89% (95% CI, 82-93%) for patients with elevated vs normal beta2M levels respectively (p<0.001). Cox regression analysis showed that beta2M level had an independent and stable prognostic value (HR=3.0; 95%CI, 1.6-5.7). In a multivariate analysis the impact of beta2M level on survival was independent of FLIPI score, with a HR of 2.94 (95% CI, 1.54-5.62)., Interpretation and Conclusions: Our results demonstrate that in patients treated in the pre-rituximabera, beta2M level was an independent prognostic marker in addition to FLIPI score. We thus suggest that beta2M be routinely assessed and tested in future prognostic studies of FL patients treated with combination chemotherapy and anti-CD20 agents.
- Published
- 2007
- Full Text
- View/download PDF
12. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease.
- Author
-
Gallamini A, Rigacci L, Merli F, Nassi L, Bosi A, Capodanno I, Luminari S, Vitolo U, Sancetta R, Iannitto E, Trentin L, Stelitano C, Tavera S, Biggi A, Castagnoli A, Versari A, Gregianin M, Pelosi E, Torchio P, and Levis A
- Subjects
- Adolescent, Adult, Aged, Disease-Free Survival, Female, Fluorodeoxyglucose F18, Humans, Male, Middle Aged, Neoplasm Staging methods, Positron-Emission Tomography standards, Treatment Outcome, Hodgkin Disease diagnosis, Hodgkin Disease therapy, Positron-Emission Tomography methods, Predictive Value of Tests
- Abstract
Background and Objectives: We explored the predictive value on therapy outcome of an early evaluation of treatment response by 18F-fluorodeoxyglucose position emission tomography (18F-FDG-PET) scan performed after two courses of conventional standard-dose chemotherapy in advanced-stage Hodgkin's disease., Design and Methods: One hundred and eight patients with newly-diagnosed Hodgkin's disease in stage IIA with adverse prognostic factors, or in stage IIB through IVB, were re-staged with FDG-PET after two cycles of ABVD (PET-2). The end-point of the study was the predictive value of PET-2 on 2-year progression-free survival and 2-year failure-free survival. No treatment variation based only on PET-2 results was allowed., Results: Eighty-eight patients attained complete remission (CR) while 20 showed disease progression during therapy or within 6 months after having reached CR; one patient relapsed. PET-2 was positive in 20 patients: 17 progressed during therapy, one relapsed and two remained in CR. By contrast, 85/88 (97%) patients with a negative PET-2 remained in CR; three progressed or relapsed early after the end of the chemotherapy. Thus, the positive predictive value of a PET-2 was 90% and the negative predictive value was 97%. The sensitivity, specificity and overall accuracy of PET-2 were 86%, 98% and 95%, respectively. The 2-year probability of failure-free survival for PET-2 negative and for PET-2 positive patients was 96% and 6%, respectively (log rank test = 116.7, p < 0.01)., Interpretation and Conclusions: 18F-FDG-PET scan performed after two courses of conventional standard-dose chemotherapy in advanced-stage Hodgkin's disease was able to predict treatment outcome in 103/108 (95%) of the patients.
- Published
- 2006
13. Quality of life assessment in elderly patients with aggressive non-Hodgkin's Lymphoma treated with anthracycline-containing regimens. Report of a prospective study by the Intergruppo Italiano Linfomi.
- Author
-
Merli F, Bertini M, Luminari S, Mozzana R, Bertè R, Trottini M, Stelitano C, Botto B, Pizzuti M, Quintana G, De Paoli A, and Federico M
- Subjects
- Aged, Anthracyclines administration & dosage, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Appetite, Bleomycin administration & dosage, Cyclophosphamide administration & dosage, Epirubicin administration & dosage, Etoposide administration & dosage, Female, Humans, Lymphoma, Non-Hodgkin psychology, Male, Neoplasm Staging, Pain, Prednisone administration & dosage, Sleep, Surveys and Questionnaires, Vinblastine administration & dosage, Vincristine administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Lymphoma, Non-Hodgkin drug therapy, Lymphoma, Non-Hodgkin physiopathology, Quality of Life
- Abstract
Background and Objectives: The aim of this study was to evaluate quality of life (QOL) in a group of elderly patients (> 65 years) with aggressive non-Hodgkin's lymphoma (NHL) treated with chemotherapy regimens containing anthracyclines., Design and Methods: QOL was evaluated in a population of elderly patients with aggressive NHL enrolled in a phase III clinical trial run by the Intergruppo Italiano Linfomi (IIL) from 1996 to 1999 to compare two different anthracycline-containing regimens (mini-CEOP vs P-VEBEC). The EORTC-QLQ-C30 questionnaire, which has already been validated in oncology, was used. The questionnaire was administered at the time of diagnosis, half way through the chemotherapy and at the time of restaging., Results: Ninety-one patients completed pre-therapy and post-therapy questionnaires and they are the subject of this report. Baseline QOL assessment showed a strong correlation of poor values of QOL with anemia and high risk according to the International Prognostic Index (IPI). At the end of treatment no functional scales showed worse values. A significant improvement was observed for pain (p=0.003), appetite (p=0.006), sleep (p=0.015) and global health (p=0.027). Considering only the 50 patients who achieved a complete remission (CR), an improvement was also recorded for emotional state (p=0.10), role (p=0.05), constipation (p=0.04) and global QOL (p=0.05)., Interpretation and Conclusions: The EORTC-QLQ-C30 is feasible even in a population of elderly patients, in whom it had never been tested before. The improvement of QOL at the end of the treatment demonstrated that the symptoms of the disease have a greater negative influence on the patient's life than do the side effects of the therapy.
- Published
- 2004
14. Expression of CD10 by B-chronic lymphocytic leukemia cells undergoing apoptosis in vivo and in vitro.
- Author
-
Morabito F, Mangiola M, Rapezzi D, Zupo S, Oliva BM, Ferraris AM, Spriano M, Rossi E, Stelitano C, Callea V, Cutrona G, and Ferrarini M
- Subjects
- ADP-ribosyl Cyclase immunology, ADP-ribosyl Cyclase metabolism, ADP-ribosyl Cyclase 1, Amino Acid Chloromethyl Ketones pharmacology, Antibodies pharmacology, Antibodies, Monoclonal pharmacology, Antigens, CD immunology, Antigens, CD metabolism, Apoptosis drug effects, Apoptosis genetics, Apoptosis immunology, B-Lymphocytes chemistry, B-Lymphocytes metabolism, Cell Line, Tumor, Etoposide pharmacology, Gene Expression Regulation, Neoplastic drug effects, Gene Expression Regulation, Neoplastic immunology, Humans, Immunoglobulin A pharmacology, Immunoglobulin D pharmacology, Immunoglobulin M pharmacology, Leukemia, Lymphocytic, Chronic, B-Cell genetics, Leukemia, Lymphocytic, Chronic, B-Cell pathology, Membrane Glycoproteins, Palatine Tonsil, Vidarabine pharmacology, Apoptosis physiology, Leukemia, Lymphocytic, Chronic, B-Cell metabolism, Neprilysin biosynthesis, Vidarabine analogs & derivatives
- Abstract
Background and Objectives: B-cell chronic lymphocytic leukemia (B-CLL) is an accumulating disease of slowly proliferating cells. CD10 is not normally expressed on the surface of B-CLL cells. The aim of this study was to ascertain whether B-CLL cells, induced into apoptosis, expressed surface CD10, since a correlation between apoptosis and CD10 expression has been demonstrated., Design and Methods: Peripheral blood cells from 31 untreated B-CLL patients were induced into apoptosis by etoposide, fludarabine or Ga(mu)-Ab treatment and tested for CD10 expression by flow cytometry. Normal CD5+ B cells were also induced into apoptosis and tested for CD10 expression., Results: CD10 positive cells were absent in B-CLL cell suspensions, but were detected following in vitro culture, and their appearance paralleled that of apoptotic cells. Treatment with etoposide, fludarabine or Ga(mu)-Ab enhanced both apoptosis and CD10 expression. Inhibition of apoptosis by VAD-fmk or Ga(delta)-Ab prevented CD10 expression. Cell separation tests following induction of apoptosis demonstrated that CD10+ cells were apoptotic. CD10+ cells were observed in the peripheral blood of two patients within a few hours following fludarabine infusion. In another patient, who failed to respond, no CD10+ cells were seen. Expression of CD10 was observed also in normal CD5+ B cells when these were induced into apoptosis., Interpretation and Conclusions: This study demonstrates that B-CLL cells, as well as normal CD5+ B cells, become CD10+ following apoptosis induction in vitro. Some of the data obtained also suggest a use for CD10 to monitor apoptosis of B-CLL in a clinical setting.
- Published
- 2003
15. Simultaneous expression of CD38 and its ligand CD31 by chronic lymphocytic leukemia B-cells: anecdotal observation or pathogenetic hypothesis for the clinical outcome?
- Author
-
Morabito F, Mangiola M, Stelitano C, Deaglio S, Callea V, and Malavasi F
- Subjects
- ADP-ribosyl Cyclase 1, Adult, Aged, Aged, 80 and over, Antigens, Neoplasm biosynthesis, Female, Humans, Male, Membrane Glycoproteins, Middle Aged, Prognosis, Treatment Outcome, ADP-ribosyl Cyclase biosynthesis, Antigens, CD biosynthesis, Leukemia, Lymphocytic, Chronic, B-Cell metabolism, Platelet Endothelial Cell Adhesion Molecule-1 biosynthesis
- Published
- 2003
16. Feasibility of a mixed inpatient-outpatient model of peripheral blood stem cell transplantation for multiple myeloma.
- Author
-
Morabito F, Martino M, Stelitano C, Oliva E, Kropp M, Irrera G, Console G, Fujo M, Messina G, Molica S, Callea V, and Iacopino P
- Subjects
- Ambulatory Care, Feasibility Studies, Female, Graft Survival, Hospitalization, Humans, Male, Middle Aged, Multiple Myeloma complications, Peripheral Blood Stem Cell Transplantation adverse effects, Treatment Outcome, Models, Organizational, Multiple Myeloma therapy, Patient Care methods, Peripheral Blood Stem Cell Transplantation methods
- Abstract
Background and Objectives: A progressively growing number of peripheral blood stem cell transplants (PBSCTs) are being performed in patients with newly diagnosed multiple myeloma (MM) since they are ever more frequently being offered as up-front therapy. Furthermore, there are considerable concerns regarding the appropriate use of health care resources in order to reduce costs associated with PBSCT. One of the strategies attempted to reach this goal is outpatient-based PBSCT., Design and Methods: The aim of this study was to analyze the feasibility of a mixed inpatient-outpatient model (MIOM) for MM patients receiving high-dose melphalan, and homogeneously undergoing autologous PBSCT, antimicrobial and antiviral prophylaxis and post-transplant growth factor treatment. Furthermore, we retrospectively compared results of the MIOM with those of the traditional total inpatient model (TIM)., Results: MIOM was applied for 60 transplants in a total of 29 MM patients. Results were compared with retrospective data concerning the traditional TIM for 40 transplants (27 MM patients). MIOM cases were older than TIM ones (55.3 6.3 years vs 49.6 9.2 years, p=0.01), but were comparable for sex and disease status. Granulocyte recovery time was shorter in the MIOM group (9.0 0.7 vs 9.7 1.2 days, p=0.004), while a similar number of stem cells were infused. There was no difference in platelet engraftment. The number of episodes and duration of grade II-IV mucositis were similar in both groups. Fever occurred in fewer MIOM cases (25% v 51.6%, p=0.02), while its duration was similar. In multivariate analysis, mucositis (grades II-IV) was the sole independent predictor of fever development (p=0.002). Half of the MIOM cases never required re-admission, 26 were re-admitted (median hospital stay 9 days) and 4 cases were not discharged (median hospital stay 15 days). The median time to discharge of TIM cases was 20 days. Non-hematologic toxicities were low in both groups., Interpretation and Conclusions: Since outpatient management and liberal hospitalization criteria have resulted in safe conduct of MIOM transplants, this program can be safely offered to MM patients.
- Published
- 2002
17. Peripheral blood CD38 expression predicts time to progression in B-cell chronic lymphocytic leukemia after first-line therapy with high-dose chlorambucil.
- Author
-
Morabito F, Mangiola M, Stelitano C, Deaglio S, Callea V, and Malavasi F
- Subjects
- ADP-ribosyl Cyclase, ADP-ribosyl Cyclase 1, Adult, Antineoplastic Agents, Alkylating administration & dosage, Chlorambucil administration & dosage, Disease-Free Survival, Female, Fluorescent Antibody Technique, Indirect, Humans, Leukemia, Lymphocytic, Chronic, B-Cell metabolism, Leukemia, Lymphocytic, Chronic, B-Cell mortality, Leukemia, Lymphocytic, Chronic, B-Cell pathology, Life Tables, Male, Membrane Glycoproteins, Middle Aged, Prognosis, Remission Induction, Treatment Outcome, Antigens, CD, Antigens, Differentiation analysis, Antineoplastic Agents, Alkylating therapeutic use, B-Lymphocytes chemistry, Chlorambucil therapeutic use, Leukemia, Lymphocytic, Chronic, B-Cell drug therapy, NAD+ Nucleosidase analysis, Neoplastic Stem Cells chemistry
- Abstract
CD38 expression by B-cell chronic lymphocytic leukemia (B-CLL) cells has been the focus of several recent studies. The aim of this study was to evaluate the prognostic impact of CD38 expression by peripheral blood lymphocytes on progression-free survival after first-line therapy with high-dose chlorambucil in 53 previously untreated patients affected by typical CD5+ CD23+ B-CLL.
- Published
- 2002
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.